12:00 AM
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vyvanse lisdexamfetamine dimesylate: Development discontinued

Shire disclosed in its 1Q13 earnings that it discontinued development of lisdexamfetamine dimesylate for negative symptoms of schizophrenia "after a review and prioritization" of its development portfolio and "taking into account investment requirement for recent acquisitions." Shire said it began a Phase III program of lisdexamfetamine dimesylate in the indication in 4Q12,...

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >